60 Degrees Pharmaceuticals (Nasdaq: SXTP) announced that all patients in its expanded access clinical trial for relapsing babesiosis were cured following treatment with its tafenoquine-based regimen, reinforcing prior Yale research showing near-100% success in difficult-to-treat immunosuppressed patients. With incidence of the serious tick-borne disease rising and no FDA-approved therapies available, the company is calling for updated treatment guidelines as the promising data strengthens the case for tafenoquine’s role in future care standards.

Trinity Biotech (Nasdaq: TRIB) reported major technical milestones for its next-generation CGM+ continuous glucose monitoring platform, including improved measurement accuracy, AI-powered multimodal sensing, and a modular design aimed at lowering costs and expanding adoption. With more than 650 days of clinical testing supporting the technology, the company is preparing for a pivotal clinical trial in 2026 as it targets the rapidly expanding $15B global CGM market and broader AI-driven digital health opportunities.

Blue Gold (Nasdaq: BGL) reported a successful beta for its Standard Gold Coin (SGC) and ONE Wallet platform, a blockchain-based ecosystem that allows users to buy, hold, and transfer tokenized gold backed by allocated bullion stored at Brinks Dubai. With strong early engagement and full on-chain transparency linking tokens to physical gold bars, the company is preparing for a public launch in Q2 2026 as it looks to modernize global gold ownership through digital assets.

Calidi Biotherapeutics (Nasdaq: CLDI) highlighted its proprietary, scalable manufacturing process for CLD-401 at the Bioprocessing Summit, with FDA feedback supporting the company’s approach as it advances the RedTail platform candidate toward clinical development. Designed to systemically target tumors and deliver IL-15 superagonist to activate immune responses, CLD-401 is currently in IND-enabling studies with an Investigational New Drug application planned by the end of 2026.